logo-loader
viewCanntab Therapeutics Ltd

Full interview: Canntab Therapeutics granted cannabis research licence from Health Canada

Canntab Therapeutics Limited (CSE:PILL-OTCQB: CTABF) Co-Founder and CFO Richard Goldstein joined Steve Darling from Proactive Vancouver on Skype to discuss the company being granted their cannabis research license from Health Canada. Goldstein talks about what this license allows Canntab to do and what their next step is.

Goldstein also told Proactive what the company plan on for the remainder of 2020. 

Quick facts: Canntab Therapeutics Ltd

Price: 0.65 CAD

CSE:PILL
Market: CSE
Market Cap: $20.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Canntab Therapeutics gets first commercial sale with Medipharm

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.  Goldstein discusses how the...

on 06/02/2020

2 min read